Analysis of tumour levels of the EGFR as assayed by immunohistochemistry or in tumour lysates has shown that its overexpression is correlated with disease progression, poor survival and development of resistance to cytotoxic agents, being involved in over 70% of all cancers (Baselga, 2002; Jimeno and Hidalgo, 2005), specially in non-small cell lung cancer (NSCLC) and head and neck carcinoma (HNC). Here, EGFR is linked to cancer.